Use of tyrosine kinase inhibitors for paediatric Philadelphia chromosome-positive acute lymphoblastic leukaemia: a systematic review and meta-analysis
Objectives To investigate the effectiveness and safety of tyrosine kinase inhibitors (TKIs) in the management of paediatric Philadelphia chromosome-positive acute lymphoblastic leukaemia (Ph+ALL).Design A systematic review and meta-analysis.Data sources Electronic searches were conducted on CENTRAL,...
Main Authors: | Lingli Zhang, Yiping Zhu, Min Chen, Yunzhu Lin, Tianzi Tengwang |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2021-01-01
|
Series: | BMJ Open |
Online Access: | https://bmjopen.bmj.com/content/11/1/e042814.full |
Similar Items
-
TYROSINE KINASE INHIBITORS PLUS HYPER-CVAD FOR THE FRONTLINE TREATMENT OF PATIENTS WITH PHILADELPHIA CHROMOSOME POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA
by: R.D. Portugal, et al.
Published: (2020-11-01) -
Philadelphia chromosome-negative B-cell acute lymphoblastic leukaemia with kinase fusions in Taiwan
by: Yin-Chen Hsu, et al.
Published: (2021-03-01) -
Patients in Focus: What's Relevant for Chronic Myeloid Leukaemia and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukaemia?
by: Michele Baccarani, et al.
Published: (2017-08-01) -
Role of BCR-ABL1 isoforms on the prognosis of Philadelphia chromosome positive acute lymphoblastic leukemia in the tyrosine kinase inhibitor era: A meta-analysis.
by: Wanhua Zhang, et al.
Published: (2020-01-01) -
Correlation between deletion of the CDKN2 gene and tyrosine kinase inhibitor resistance in adult Philadelphia chromosome-positive acute lymphoblastic leukemia
by: Na Xu, et al.
Published: (2016-04-01)